Giant cell arteritis (GCA) is the most common form of vasculitis in individuals older than 50 years in Western countries. To shed light onto the genetic background influencing susceptibility for GCA, we performed a genome-wide association screening in a well-powered study cohort. After imputation, 1,844,133 genetic variants were analysed in 2,134 cases and 9,125 unaffected controls from ten independent populations of European ancestry. Our data confirmed HLA class II as the strongest associated region (independent signals: rs9268905, P = 1.94E-54, per-allele OR = 1.79; and rs9275592, P = 1.14E-40, OR = 2.08). Additionally, PLG and P4HA2 were identified as GCA risk genes at the genome-wide level of significance (rs4252134, P = 1.23E-10, OR = 1.28; and rs128738, P = 4.60E-09, OR = 1.32, respectively).
A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with giant cell arteritis 
Introduction
During the last decade, genome-wide association studies (GWAS), in which common genetic variation across the whole genome is interrogated in a hypothesisfree fashion, were a breakthrough in biomedical research methodology and have led to the identification of thousands of robust genetic associations within a wide spectrum of complex human diseases 1 . However, some diseases of low prevalence have received less attention due to the difficulty in recruiting well-powered study cohorts, even though rare diseases result in a significant disease burden. An example is giant cell arteritis (GCA [MIM 187360]), the most common form of vasculitis in Western countries in people over 50 years old. GCA is characterised by chronic inflammation of large arteries, such as the aorta, the carotid arteries and its extracranial branches, which may lead to severe clinical sequelae if not treated promptly, including visual loss, scalp and tongue necrosis, aortic dissection/rupture or cerebral infarction [2] [3] [4] . Although the genetic component of GCA has previously been investigated following a candidate gene approach, most of the described genetic associations were based on underpowered analyses and usually failed to be replicated in independent populations [6] [7] [8] . Taking advantage of the large sample collection that this collaboration has enabled, comprising ten independent populations of European ancestry that cover the whole gradient for prevalence of the disease, we performed an agnostic genetic study in GCA at the genome-wide level.
Subjects and Methods

Study population
This study included a total of 2,134 GCA cases and 9,125 unaffected controls from ten independent populations of European ancestry: Spain ( . In addition, the diagnosis was subsequently confirmed by either a biopsy of the temporal artery (89.83%) or arterial imaging (10.17%) consistent with GCA. A detailed description of the main clinical characteristics of the different case cohorts is provided in Table S1 . All participants signed an informed consent form before being enrolled in the study. The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) of all participant centres.
Genotyping and quality controls
Genomic DNA from peripheral blood samples of all GCA cases as well as the Spanish and Irish controls were screened using the GWAS platform "Infinium® HumanCore Beadchip" in an iScan System and the Genotyping Module (v.1.9) of the GenomeStudio software (Illumina, Inc). The genotyping was conducted in the Genomics and Genotyping Unit of the Pfizer-University of Granada-Junta de Andalucía
Centre for Genomics and Oncological Research (GENYO, Granada, Spain), following the manufacturer's protocol. Single-nucleotide polymorphisms (SNP) with a cluster separation <0.4 were removed after the calling.
Genotyping data from the remaining control population were obtained from 9 cohorts of geographically matched European ancestries included in previous studies [10] [11] [12] [13] [14] [15] [16] [17] ( Table S2 ).
All studies were subjected to stringent quality-control measures separately based on the same analytical protocol using PLINK v.1.07 18 . Specifically, we filtered out SNPs with call rates <0.98, minor allele frequencies (MAF) <0.01, and those that deviated from Hardy-Weinberg equilibrium (HWE; P<0.001 in both cases and controls).
Similarly, samples with less than 95% of successfully called SNPs, and one subject per pair of first-degree relatives (identity by descent > 0.4) were removed. Sex chromosomes were also excluded from the analysis. 
Imputation methods
After applying the QC filters, whole-genome SNP genotype imputation was carried out with IMPUTE v.2 19 using the combined 1000 Genome Project Phase III (1KGPh3) data as reference panel, which includes 2,504 individuals 20 . In brief, for each individual dataset, the strand orientation, chromosome position, and SNP identification were updated in PLINK to match the build 37 (HG19) of the 1KGPh3. Next, PLINK-formatted files were converted to the appropriate format with GTOOL and the genotyping data were split into chunks of 50,000 Mb covering whole-genome regions. Imputation was done separately for each study. To ensure quality of imputed SNPs, the most likely call was used for merging genotypes, but only if the most likely call exceeded a probability threshold of 0.9 (the genotype was set to missing otherwise). As the individual imputation of each case/control set could lead to stratification, imputed data were also subjected to rigorous quality filters in PLINK, including removal of SNPs with call rates <0.98, MAFs <0.01, and those that were not in HWE (P<0.001). Moreover, after merging case/control sets, singleton SNPs and those showing strong evidence of discordance in the genotype distribution between cases and controls due to possible miscalling were removed using an in-house Perl script. Finally, principal component (PC) analyses were conducted to control for possible population stratification using PLINK and the GCTA64 and R-base software under GNU Public license v2. For that, we calculated and plotted the ten first PCs of each individual and those samples located at >4 standard deviations from the cluster centroids of each cohort were considered outliers and, consequently, excluded from the analyses.
The final numbers of individuals and SNPs that remained in the filtered datasets are shown in Table S2 . Table S3 shows the estimation of the overall statistical power of this study accordingly with the CaTS Power Calculator for Genetic Studies software, which implements the methods described in Skol et al. assuming an additive genetic model 21 .
Statistical analyses
PLINK was used to conduct all the case/control analyses. First, the genotype frequencies of all markers were compared between cases and controls of every individual dataset by logistic regression on the best-guess genotypes (>0.9 probability) assuming an additive model and using the ten first study-specific PCs and the gender as covariates. Next, a combined analysis of all studies was performed using the inverse variance weighted meta-analysis under a fixed effects model. In order to maximise the total number of SNPs analysed without compromising the consistency of the results, we tested all SNPs present in the largest GCA sample set (Spain) and in one or more additional studies (i.e. ranging from 2 to 10 studies but including always the Spanish set). A total of 1,844,133 were evaluated in the meta-analysis. To identify independent effects across associated regions, dependency analyses at the cohort level genome-wide scans were conducted in PLINK by step-wise logistic regression with adjustment for the most associated signals in the common set of SNPs, following by inverse variance weighted meta-analysis under a fixed effects model. The heterogeneity of the odds ratios (OR) across the different studies was estimated using both I 2 and Cochran's Q tests. The Manhattan plots were obtained with an in-house R script, and the zooms of the associated regions were obtained with LocusZoom v1.1 22 .
Functional annotation of associated variants
We evaluated the putative functional implications of the GCA risk loci by implementing our data with publicly available functional annotation data.
Despite the high efficiency of the imputation process, it was not possible to obtain imputed types for every known polymorphism. Therefore, in a first step, we identified all Figure 1 and Table S4 ).
Within the HLA region, the top hit was rs9268905 (P = 1.94E-54, OR = 1.79, 95% CI Figure S1 ).
Outside the HLA region, rs4252134, located in an intron of PLG at chromosome 6, represented the most strongly associated variant (P = 1.23E-10, OR = 1.28, 95% CI 1.19-1.39, Figure 2 ). Although some heterogeneity was observed between studies (I 2 =48.8), consistent OR directions of the minor allele (towards risk) were observed in all sets ( Table 1, Table S4 and Figure S2 ). Other SNPs within the gene (both intronic and exonic) also showed significant P-values, but their statistical significance was lost when conditioned on rs4252134 (Table S6 and Figure S3 ). Finally, another intronic SNP of P4HA2 at chromosome 5, rs128738, surpassed the statistical threshold (P = 4.60E-09, OR = 1.32, 95% CI 1.20-1.45). This genomic region also showed additional suggestive signals, but none of them was significant at the genome-wide level ( Figure   2 ).
To confirm the above results, we obtained direct genotypes of the whole Spanish cohort using TaqMan probes for rs128738 and two perfect proxies (r2 = 1) of rs4252134 and rs9268905 (rs4252125 and rs2395185, respectively). The overall concordance reached after comparing TaqMan types with the corresponding imputed data was 99.94% for rs128738, 99.81% for rs4252134/rs4252125, and 99.94% for rs9268905/rs2395185".
Functional annotations of proxies of the non-HLA hits
To prioritise variants that could drive the observed non-HLA associations, we identified all the SNPs in high linkage disequilibrium (LD, r 2 > 0.8) with the lead signals in the European populations of 1KGPh3 (Tables S7, S8) , and used public online annotation tools to evaluate their possible functional implications. One PLG polymorphism (rs4252125) was annotated as missense in the dbSNP database.
However, this variant was predicted to be benign according to PolyPhen-2, and showed no evidence of being potentially pathogenic after scoring the deleteriousness with CADD (raw score = -0.63, PHRED-like scaled C-score = 0.104). Then, using
RegulomeDB, we identified those SNPs overlapping with known and predicted DNA elements with a higher probability of regulatory effects (score ≤ 3) (Tables S7, S8) , and performed a detailed functional annotation of these tagger variants and the lead SNPs using HaploReg ( Table 2 and Tables S9-S11 ). Most of them overlapped with DNase hypersensitivity sites and histone marks enriched at promoters and enhancers ( Table   2) . Interestingly, some of these annotations were related to cell types and tissues involved in GCA pathophysiology. For example, PLG rs4252135 co-localised with DNase peaks in different immune cell lines and had a predicted enhancer chromatin state in lymphoblastoid cells (Tables S9, S10) . A higher enrichment of promoter and enhancer epigenetic marks in these tissues was observed for the prioritised P4HA2 variants (Table S9) . Specifically, the lead signal rs128738 overlapped with enhancer histone marks in immune cells and with the imputed Transcription 3' Enhancer mark in the aorta (Table S10) . Additionally, P4HA2 rs156023 showed evidence of influencing enhancer activity in hematopoietic stem cells and neutrophils as well as promoter activity in mononuclear cells and monocytes (Tables S9, S10 ).
In addition, key regulatory proteins (some of them related to the immune response)
bound by ChIP-seq experiments as well as relevant motif disruptions were reported in most cases ( Table 2) .
Consequently, most prioritised SNPs also correlated with eQTL effects in peripheral blood monocytes and lymphoblastoid cells ( Table 2 and Table S11 ). Interestingly, rs101194 and rs152054 were reported to affect P4HA2 expression in arterial tissues in the Genotype-Tissue Expression (GTEx) study 32 , with rs101194 specifically acting as cis-eQTL in the aorta (Table S11) .
Candidate genes and pathway analysis
We also checked the statistical significance in our GWAS of previously described Tables S12, S13 ). Subsequently, we accomplished a proteinprotein interaction (PPI) and biological pathway enrichment analysis with those candidate hits showing statistically significant signals after correction for multiple testing in our GWAS ( Table S13 ). The molecular network of the selected proteins had significantly more interactions than expected (number of nodes: 13, number of edges:
14, average node degree: 2.15, clustering coefficient: 0.851, expected number of edges: 3, PPI enrichment P = 1.13E-06; Figure 3) . Interestingly, PLG represented a relevant node showing evidence of interaction with different proteins (e.g. NOS3, IL-6, and TNF) (Figure 3) . Regarding the functional enrichments of the network, the most significantly associated GO processes were those related to regulation of both cell-cell adhesion and the immune/inflammatory response ( Table S14) .
Discussion
This study represents an unbiased screening of genetic variation in GCA at the genome-wide level. GCA was one of the few types of vasculitis in which GWAS data were not available. Therefore, the results presented here may help to better understand the pathogenic mechanisms underlying this condition and its genetic similarities with other vasculitides. In this sense, our data reinforces the idea of GCA as an archetypal HLA class II disease mediated by an antigen-driven immune response Regarding the non-HLA associations, several variants within the PLG gene were firmly associated with risk to develop GCA at the genome-wide level of significance in this study, although they all were in high LD and represented a single signal according to the dependence analysis. This gene encodes a secreted blood zymogen that can be converted through a complex conformational modification into two different active proteins, plasmin and angiostatin 35 . The plasminogen system has an important role in a wide spectrum of physiological processes, including wound healing, fibrinolysis, angiogenesis, and lymphocyte recruitment and inflammation via production of cytokines and reactive oxygen species 36; 37 , all of them relevant processes in GCA 38 .
Considering the opposite roles of plasmin and angiostatin in the induction of pro- 
